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Abstract
Background: The 9th edition of the American College of Chest Physicians’ Antithrombotic Therapy and Prevention
of Thrombosis guidelines emphasize the importance of considering the risk–benefit ratio of “patient-important”
outcomes. However, little is known about patients’ perception and understanding regarding the different outcomes of
antithrombotic treatment after orthopedic surgery, and the factors that influence their decision to use these
treatments. Using a series of semi-structured interviews, we explored patients’ understanding and perception
concerning the benefits and risks of antithrombotic treatment for the prevention of venous thromboembolism
(VTE) after joint replacement surgery.
Methods: A series of semi-structured interviews were conducted with patients who had undergone knee or
hip replacement surgery at a tertiary care hospital (Brigham and Women’s Hospital, Boston, MA) in 2014.
Discussions were recorded and transcribed. Two investigators independently coded and analyzed the data to
identify important themes and concepts using the constant comparative method.
Results: Of 64 patients who were invited, 12 patients (19 %) completed the interviews. The majority of patients (92 %)
were aware of the benefits of antithrombotic therapy for reducing the risk of blood clots, while less than half of them
had a clear understanding of deep vein thrombosis and pulmonary embolism. While all patients were aware of risk of
minor bleeding, only 6 patients (50 %) considered the risk of major bleeding as a possible side effect of antithrombotic
treatment. Overall, patients perceived bleeding as a less important outcome than a thrombotic event. The lack of
awareness about the risk of major bleeding, the assumption that a short-term exposure would not meaningfully
affect bleeding risk, and the assumption that bleeding is a controllable event influenced their perception. Most
patients (83 %) stated that their decision to use antithrombotic medications was mainly based on the trust in
their physician’s expertise.
Conclusions: Patients perceived thrombotic events as more important outcomes than bleeding events. Patients’
understanding of thrombotic and bleeding events varies and may play a key role in their preferences. The
majority of patients stated that trust in their physician’s expertise had a large influence on their decision to
use antithrombotic medications.
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Background
Patients who undergo major orthopedic surgery (e.g.
hip or knee replacement) are at risk of venous
thromboembolism (VTE), which includes deep vein
thrombosis (DVT) and pulmonary embolism (PE).
The cumulative 35-day post-operative risks of symp-
tomatic VTE, DVT, and PE are estimated to be as
high as 4.3 %, 2.8 %, and 1.5 %, respectively [1].
Prophylactic antithrombotic treatment has been shown to
decrease these risks to 1.8 %, 1.55 %, and 0.55 %, for
VTE, DVT and PE respectively [1]. Although the re-
sults of meta-analyses of randomized clinical trials
strongly support the benefit of prophylactic anticoa-
gulation for reducing the risk of symptomatic VTE
and fatal PE, the evidence concerning bleeding risk
associated with prophylactic anticoagulation is not
consistent [2, 3]. The recommendations of the 9th
edition of the American College of Chest Physicians
(ACCP) Guidelines on Antithrombotic Therapy and
Prevention of Thrombosis emphasize the importance
of considering the risk–benefit ratio of “patient-im-
portant outcomes”. These guidelines suggest that benefits
of prophylactic antithrombotic treatment outweigh poten-
tial risks only in patients who are at sufficiently high risk
of developing symptomatic VTE [4, 5].
Physicians’ decisions about using prophylactic treat-
ment are usually based on the patient’s risk for develop-
ing VTE, expected benefits and risks of antithrombotic
drugs, and factors such as treatment modality and dur-
ation. An implicit element in this process is the physi-
cians’ awareness about outcomes and factors that are
important for patients when deciding about antithrom-
botic therapy. However, there is little information about
patients’ understanding and perception of the benefits,
risks, and other factors that can influence their prefer-
ences for using or not using antithrombotic therapy [1].
Such information would be particularly valuable given
the consistently reported underuse of antithrombotic
medications [6, 7]. Exploring patients’ perceptions and
understanding of different outcomes associated with
antithrombotic therapy may provide useful informa-
tion to physicians for making more patient-centered
prescribing decisions. In this exploratory study, we in-
vestigated patients’ understanding and perception in
regard to the benefits and risks of antithrombotic
drugs for prevention of VTE after a joint replacement
surgery using a qualitative approach.
Methods
Participants
This study involved a series of in-person or phone in-
terviews with patients who had recently undergone
knee or hip replacement surgery at a tertiary care hos-
pital (Brigham and Women’s Hospital, Boston, MA).
Using the hospital’s centralized clinical data registry
(the Partners’ Research Patient Data Registry (RPDR)),
we identified an initial list of patients who had under-
gone hip or knee replacement surgery between January
and June 2014, and who were 18 years of age or older.
Through the registry, we gathered data on the charac-
teristics and the contact information of patients who
had undergone surgery with one of two orthopedic
surgeons that were part of the research team. Upon
receiving their surgeons’ permission, patients were in-
vited by mail to participate in a 30-min interview.
The invitation letter briefly described the purpose of
the study. The letter also stated that patients could
refuse to answer any question or decide to withdraw
at any point during the study period without any im-
pact on the care that they receive from the hospital.
All participants were offered a $50 honorarium in the
form of a gift card upon completion of the interview.
Patients who responded positively to our invitation
were contacted by our study coordinator to arrange
an interview time. Interviewing was planned to be
discontinued once 15 patients agreed to participate or
whenever the study team concluded that no new
themes or concepts would arise during the interviews.
To ensure adequate time for reviewing, study infor-
mation and fact sheets were sent to participants at
least one week prior to conducting the interview and
participants provided their consent at the beginning
of each session. The protocol for this study was ap-
proved by the Behavioral Research Ethics Board of
the Brigham and Women’s Hospital.
Interview procedure
Patients initially were invited for in-person interviews
at the tertiary care hospital. In a follow-up contact
they were also offered the option to interview via
phone. We used a semi-structured interview approach
with a list of questions to guide discussion during the
interviews (Please see Appendix). These questions
were designed to address our study objective. In par-
ticular, we asked whether patients were aware and
had clear understanding of potential complications
that might occur following the surgical procedure, e.g.
DVT and PE, in contrast with unrelated but possibly
more familiar conditions, e.g. stroke and myocardial
infarction (MI); whether they knew about the benefits
and risks of using “blood thinners”; and what factors
affected their decisions to comply with (or not com-
ply with) prophylactic antithrombotic treatment. In
addition to these predefined questions, both patients
and interviewer had the opportunity to discuss issues
that they deemed to be relevant to the study topic as
they emerged during the interviews.
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Analysis
All discussions were digitally recorded, transcribed,
and analyzed using the constant comparative method
[8–10]. Transcripts were initially reviewed with the
aim of developing an overall understanding of the
scope and content of data. We identified issues re-
quiring further clarification, which were included as
discussion topics in the subsequent interviews. Subse-
quently, a line-by-line analysis of transcripts was con-
ducted and codes were assigned to phrases and sentences
as a concept became apparent. The appropriateness of
the code assignments was assessed by reviewing the
previously coded data and ascertaining consistent as-
signment of codes to concepts. As more data were
reviewed, the code structure was modified inductively
by refining the existing codes and adding new codes
when necessary. Data were hand-coded and reviewed
separately by two investigators (MN and CP) to iden-
tify major concepts and emerging themes. All discrep-
ancies were resolved by in depth discussion of issues
among three investigators (MN, CP, and EP).
Results
Of 64 patients who were invited for interviews, 12 patients
(19 %) responded back and all completed an interview
(five in-person and seven phone interviews). Table 1 pro-
vides the demographic characteristics of the patients who
were invited and those who participated in interviews. Pa-
tients who were 65 years and older and females were more
likely to participate in the interviews. Race and primary in-
surance seem to be well balanced across patients who par-
ticipated and did not participate in interviews.
Patients’ understanding of VTE
Among the 12 patients who completed interviews, 8
(67 %) stated that they were informed about potential
complications (e.g. risk of blood clots) prior to surgery
(Table 2). Only 6 patients (50 %) and 5 patients (42 %)
had a clear understanding of DVT and PE, respectively,
and described those conditions as being “a clot that
forms in one of your veins that could break off and
travel through the venous system or land in your lung”
(Patient 103). In contrast, all of the patients in our sam-
ple had a basic understanding of stroke and MI, and
were able to describe these conditions as the “loss of
control of parts of the body or drooping of the face”
(Patient 102), and “pain that feels like indigestion, you
can have pain that starts in your chest and radiates out
into I think it’s your left arm”. (Patient 112)
Patients’ perceptions about the benefits of
antithrombotic therapy
Eleven patients out of 12 (92 %) were aware of the bene-
fits of antithrombotic therapy. These were generally
described in terms of a reduction in the risk of blood
clot formation after orthopedic surgery due to thinning
of the blood. However, 7 out of 12 patients (58 %) as-
sumed that prophylactic antithrombotic therapy could
also reduce the risk of stroke and MI:
“I know the benefits are it thins the blood. Therefore it
makes it harder for a clot to form.” (Patient 102)
“Not having a stroke or a heart attack or a pulmonary
embolism! Or having a clot so big that it blocks your
leg. Then you have to have it taken care of.” (Patient 104)
“I know that the blood clot was a strong possibility
after something like that and that you needed to take
a blood thinner.” (Patient 106)
Patients’ perceptions about the risks of antithrombotic
therapy
While all patients mentioned the risk of excess bleeding
in case of injury and bruising as a possible side effect of
antithrombotic treatments, only 6 patients (50 %) con-
sidered the risk of major bleeding events. Patients, in
general, described the risk of bleeding associated with
Table 1 Characteristics of patients who were contacted and
participated in the interviews
Patients who
participated in
interviews (n = 12)
Patients who were invited
but did not participate
in interviews (n = 52)
n % n %
Age (years)
≤65 4 33 % 26 50 %
65-69 3 25 % 9 17 %
70-75 2 17 % 12 23 %
75-80 1 8 % 3 6 %
≥80 2 17 % 2 4 %
Female 9 75 % 23 44 %
Race (Black or African
American)
1 8 % 6 12 %
Medicare as primary
insurance
7 58 % 25 48 %
Type of surgery
Hip replacement 9 75 %
Knee replacement 3 25 %
Prescribed antithrombotic medicatixon
Warfarin 9 75 %
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antithrombotic therapies as a consequence of “their
blood becoming too thin”:
“I know; I’m primarily familiar with the risks. I know
that you are more prone to bruising and bleeding if
you cut yourself at all or like injure yourself at all.”
(Patient 109)
“The risk would be that you’d bleed a lot if you got
cut. But other than that I don’t know.” (Patient 102)
Only half of patients acknowledged serious bleeding as
a possible side effect of antithrombotic therapy:
“Well, [INR] has to be kept at a certain level or
else your blood’s too thin. I guess you could have a
cerebral hemorrhage or some other kind of bleeding.”
(Patient 103)
“I do know that they can make you bleed too much.
That’s one of the biggest. Sometimes you don’t know
because it can be internal you know and you can
bleed into your gut.” (Patient 104)
“I know that there’s a risk of bleeding internally and
externally and not being able to stop it when you’re on
Coumadin. And that things like cuts and falls that are
very routine can be very serious when you’re on
Coumadin.” (Patient 112)
“There are a lot of side effects. But my dad was on it
and you know he would bleed terribly. He fell once
and cut a small artery in his lip. Oh, my lord, he bled
like crazy. I mean it thins out your blood. I did not
have as much a problem with it myself. I didn’t bruise
or anything. So I don’t know what the difference is.”
(Patient 113)
Factors influencing patients’ decision to use
antithrombotic medications
All patients (100 %) stated that they used antithrombotic
medications as prescribed by their physicians. Most pa-
tients (83 %) stated that their decision to use the pre-
scribed antithrombotic medications was mainly based on
the trust in their physician’s expertise:
“If I’m going to let him go in there and take a piece of
my hip and replace it with a piece of plastic and
metal and he recommends that I take blood thinners,
I’m going to say yes.” (Patient 102)
“I took them because my doctor advised it. And I had
a lot of confidence in him based on my primary care
physician, her very high recommendation.” (Patient 112)
Patients also reported that they felt that the risk of
bleeding was not substantially high since antithrombotic
therapy only lasted for a short time period:
“I don’t feel that I was at particular risk taking them if
that’s part of it…I was only on them for a relatively
short time.” (Patient 104)
“It was broached to me as a problem that would last
for a several-week period, not a long-term problem.”
(Patient 102)
Was I [worried about risks]? No. Because I knew I
wouldn’t be on them that long. If I was on them a long
time, yes. Some people are on blood thinners for a long
time.” (Patient 104)
Patients reported that they perceived bleeding as an ad-
verse event that could be monitored, and therefore could
be controlled and reversed by stopping or modifying the
antithrombotic medication being taken. Consequently,
these patients believed that bleeding events result in less
severe consequences compared to blood clots:
“They measured my blood every day or every other
day… if it was the least bit up or down, they said take
an extra pill, or don’t take any for two days and then
we’ll do it again. You know it was monitored. So I
didn’t feel as if I was ever at risk because I was being
monitored. If I was [at] high enough [risk of] major
bleeding they would have found it immediately and
taken me off the medicine; So I felt safe that I was
being followed.” (Patient 102)
Table 2 Understanding of patients about different aspects of
VTE prophylaxis who completed interviews (n = 12)
n %
Were informed about benefits and risks of
prophylactic treatment prior to surgery
8 67 %
Were able to understand the explanations
given by physicians (self reported)
11 92 %
Had sufficient understandinga of PE 6 50 %
Had sufficient understanding of DVT 6 50 %
Had sufficient understanding of stroke and MI 12 100 %
Injection was a concern 3 25 %
Taking pills was a concern 1 8 %
Monitoring for INR was a concern 2 17 %
Considered major bleeding events as possible
side effect of prophylactic treatment
6 50 %
VTE: venous thromboembolism; PE: Pulmonary embolism; DVT: deep
vein thrombosis
aSufficient understanding was defined as knowledge about key symptoms and
general prognosis of PE, DVT, stroke, and MI
Najafzadeh et al. BMC Musculoskeletal Disorders  (2015) 16:319 Page 4 of 8
“I feel like the high bleeding is more manageable or
more easily treatable than the risks of a blood clot.”
(Patient 109)
Overall, patients appeared to consider the risk of blood
clots and their consequences to be more significant than
the risk of bleeding events. Eight patients (67 %) expli-
citly stated that they were willing to trade-off an in-
creased risk of bleeding for a reduced risk of thrombotic
events:
“I think I would go with the higher bleeding risk. It just
seems to make sense … A high bleeding risk…I can
stop taking Celebrex if I have to. I could do that and
lower my risk of bleeding.” (Patient 102)
“The blood clot is so serious. I wouldn’t want to take
that chance. Although my mother did die of a cerebral
hemorrhage so I did have some concern on the other
side about bleeding. But I think that’s a lesser risk
than the blood clot if you have to weigh the two.”
(Patient 103)
“So I think [bleeding] would’ve been the lesser of the
evils so to speak.” (Patient 106)
“For me probably more the concern was the bleeding
risk…maybe that was worrying me more than the
blood clot risk…But I think I trust my doctor… [and]
what they think is the right thing for me. I was more
concerned with the bleeding …I thought maybe if it’s
not long-term, it’s going to benefit me rather than
harm me.” (Patient 107)
A few patients stated that they were more concerned
about bleeding risk compared to risk of blood clots and
embolism. However, even the patients that did have
legitimate concerns (e.g. family bleeding history, blood
disorders) reported that they did not discuss these
concerns with their doctors. Therefore, these patients
followed their physician’s advice to use antithrombotic
medications under the assumption that no other option
was available and that their physician had carefully con-
sidered the patient’s individual profile to assure that the
benefits outweighed the risks:
“I mean I would think that a doctor would be making
a decision like that based on the individual patient.”
(Patient 109)
“I just took it because I thought they know better so it
means I can take it. But I was a little concerned with
the ITP [Idiopathic thrombocytopenic purpura] … I
didn’t really question the ulcer, that I had an ulcer
before in the stomach…the ITP was the main
[concern]. ..You say “Okay, you know where my health
issues are.” I think at that point I trust what he
decides for me.” Patient 107
Overall, treatment modality (e.g. injection vs. pills), need
for frequent monitoring, diet requirements to control po-
tential interactions with antithrombotic medications, and
cost played minimal role in patients’ willingness to use an-
tithrombotic medications after surgery.
Discussion
Physicians’ awareness of patients’ understanding and
preferences regarding the benefits and risks of anti-
thrombotic treatment can enrich the patient-physician
communication process and increase the likelihood of
making optimal treatment decisions. The large variety
of therapeutic options available for thromboprophy-
laxis following orthopedic surgery, which include low
molecular-weight heparin, fondaparinux, low-dose unfrac-
tionated heparin, warfarin, new oral anticoagulants, as-
pirin, and mechanical compression devices [ACCP 2012]
[1], and the lack of clarity regarding which prophylactic
strategy (or strategies) is/are optimal or suboptimal
[AAOS, 2012] [11], suggests that the knowledge about pa-
tients’ understanding and preferences could play a par-
ticularly relevant role in the prescribing decision. Using a
qualitative approach, we investigated the understanding
that patients have regarding VTEs such as PE and DVT,
and the factors that can influence patients’ decisions for
using (or not using) thromboprophylactic medications
that they have been prescribed.
Our results suggest that patients in our sample were
aware of the increased risk of thrombotic events after
orthopedic surgery and were able to describe the bene-
fits of antithrombotic treatment in terms of a reduction
in the risk of thrombosis by “thinning” their blood.
However, less than half of patients in our sample had a
clear understanding of DVT and PE. The majority of pa-
tients in our sample assumed that antithrombotic treat-
ment can also reduce risk of stroke and MI, a benefit
that has not been substantiated by evidence. Although
patients were generally familiar with the concept of
bleeding as a side effect of treatment, only half of them
acknowledged the possible occurrence of serious bleed-
ing. Treatment modality, need for monitoring, drug-food
interaction, and cost did not seem to have a large influ-
ence on patients’ use of thromboprophylaxis in our
sample.
Overall, patients perceived bleeding as a less important
occurrence compared to a thrombotic event and were
willing to trade additional bleeding risk in exchange for
a reduction in the risk of thrombotic events by comply-
ing with the prescribed prophylactic strategy. They
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generally viewed bleeding as a minor event that could be
monitored and controlled if necessary. This is despite
the fact that mortality rates as a result of PE and major
bleeding in patients undergoing hip and knee replace-
ment surgery are largely unknown [4]. Patients also be-
lieved that the risk of bleeding was not significant
because prophylactic antithrombotic treatment was only
prescribed for a short period of time. This suggests a dif-
ferential perception for the impact of treatment duration
on bleeding versus a thromboembolic event. Patients
generally believed that their physician had carefully con-
sidered all the risks and benefits and the individual pa-
tient’s profile in their prescription decisions. Therefore,
the large majority of patients followed their physician’s
recommendation, regardless of their individual percep-
tion about risks, benefits, and other aspects of treatment.
This finding is line with several previous studies that
have shown patient trust in their doctors to have strong
influence on medication use and adherence [12–14].
Surgeons’ attitudes towards VTE prophylaxis in surgi-
cal patients have been explored in a study by Polk et al.
[15]. Their results suggested that surgeons’ opinions
varied widely based on practice sites, modes, and spe-
cialty. However, the same study found that orthopedic
and gynecologic surgeons had less diverse opinions and
tended to agree with each other in terms of the benefit
of post-surgical thromboprophylaxis, while greater vari-
ation occurred among general and trauma surgeons.
The literature about patient preferences concerning VTE
prophylaxis is sparse [16, 17]. The 9th edition of the
American College of Chest Physicians (ACCP) Guidelines
on Antithrombotic Therapy and Prevention of Throm-
bosis emphasize the importance of considering “pa-
tient-important outcomes,” and has used the results of
a systematic review on patient values and preferences
for antithrombotic therapy to inform these guidelines
[18, 19]. However, these studies reflect patients’ values
and preferences around the prevention of thrombosis,
stroke and MI, but do not specifically explore VTE,
DVT, or PE. Only one study by Wong et al. [20] has re-
cently explored patients’ preferences regarding VTE
prophylaxis within the United States. In this study, a
sample of 227 patients hospitalized in surgical and
medical units in an academic medical center, and with
a recent prescription for thromboprophylactic medica-
tions, completed a survey to assess whether they pre-
ferred injectable versus oral medications. Based on the
findings that suggested a preference for oral medica-
tions, the authors concluded that tailoring treatment
route to patient preferences might improve compliance
with thromboprophylactic therapy. This study focused
solely on patient preferences with respect to treatment
modality, and did not explore the relative importance
of other factors on patients’ decisions to use these
treatments. In our study, we found that patients’ trust
in their physician’s recommendation and personal con-
siderations regarding the overall balance between the
risks and benefits of VTE prophylaxis are the main de-
terminants of compliance. Conversely, treatment modality
had little influence on patients’ decisions in our study.
Our study has several limitations. First, our sample
was selected from a major academic hospital in an urban
setting and all patients interviewed underwent surgery
with either one of two surgeons. Therefore, our results
may not be generalizable to other types of practices and
settings. Second, our small sample size may limit the
generalizability of our findings. However, after interview-
ing 12 patients, we observed no new theme or concept
emerging during the interviews. Third, all interviews
were conducted post-surgery and therefore, patients’
preferences may have been influenced by their experi-
ence. Third, our findings could be influenced by recall
bias as some patients may forget the details of their
interaction and communication with their care providers
over time. However, in order to reduce chances of recall
bias, we only invited patients who had undergone a sur-
gery within six month prior to interview.
This study extends the current knowledge about pa-
tients’ understanding of VTEs and their consequences,
as well as patients’ perceptions regarding the benefits,
risks, and inconveniences associated with thrombo-
prophylactic therapy. The results of this study provide
preliminary important information to inform future
research aimed at quantitatively measuring patient
preferences and the relative impact of different factors
on patients’ willingness to use VTE thromboprophy-
laxis, which will ultimately assist physicians in making
more patient-centered prescribing decisions.
Conclusions
Patients perceived thrombotic events as more important
outcomes than bleeding events. Patients’ understanding of
thrombotic and bleeding events varies and may play a key
role in their preferences. The majority of patients stated
that trust in their physician’s expertise had a large influ-
ence on their decision to use antithrombotic medications.
Data availability




1) Introduction and purpose of the study
2) Our study team
Interviewer will provide a brief explanation of the
purpose of our study.
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3) Open-ended questions
The interviewer will introduce the study team,
affiliations, and sources of funding.
Given that you have recently had a knee or hip re-
placement surgery, are you aware of any complications
that may occur after the surgery?
Has your physician explained to you what are the
possible problems that may happen after hip or knee
replacement surgery? Were you able to clearly under-
stand those explanations?
Have you ever heard the terms “pulmonary embolism”
or “deep vein thrombosis”? How do you compare those
problems with stroke or heart attack?
Has your physician discussed with you options to pre-
vent these complications? Has he prescribed any blood
thinners (for example, heparin, warfarin, dabigatran, as-
pirin)? Has he discussed the use of any pressure devices
(for example, inflatable air sleeves, or elastic compres-
sion stockings)?
Do you know what kind of benefits or risks blood
thinning medications can have? Have you informed your
doctor of any questions or concerns you had before
starting these medications?
If you have been prescribed any of these medications,
have you used them as your physician suggested? Have
you informed your doctor of any questions or concerns
after starting these medications?
What are the factors that can influence your decision
whether to use (or not to use) these medications?
Do you consider any of the following issues as some-
thing that can influence your decision to take these
medications?
I am not sure about the benefits of these medications
I am not sure about the side effects of these medica-
tions (bleeding, PE, DVT, stroke, MI)
I dislike injections
I dislike taking several pills per day
The cost is an issue for me
Abbreviations
VTE: Venous thromboembolism; DVT: Deep vein thrombosis; PE: Pulmonary
embolism; MI: Myocardial infarction.
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